Other News To Note
Friday, June 24, 2011
Sirnaomic Inc., of Gaithersburg, Md., signed a partnership agreement with Guangdong Zhongsheng Pharmaceutical Co. Ltd., of Dongguan City, China, to develop small interfering RNA for diabetic retinopathy and age-related macular degeneration. The partnership will focus on clinical development and commercialization of STP601, a Sirnaomics compound, for ocular neovascularization conditions. Guangdong Zhongsheng will commit $9.75 million including up-front and milestone payments, and Sirnaomics will also be eligible for royalty sharing.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.